Sam Waksal is ready for Act II.
The details of the scientist-turned-CEO's first act are well known: founding ImClone, the maker of the cancer drug Erbitux, then insider trading charges and a five-year prison term—a scandal that also brought jail time for his friend Martha Stewart.
Waksal emerged from prison in 2009, the year after ImClone was sold to Eli Lilly for $6.5 billion. He's since raised $500 million in debt and equity and founded a new drug company, Kadmon, a closely held firm he's led as chairman and CEO.
As part of his sentence, Waksal was barred permanently by the Securities and Exchange Commission from serving as an officer or director of any public company.
Now, Kadmon has plans to go public. The company aims to file a form S-1 with the SEC by the end of this year and will move forward with an initial public offering, Waksal said in an interview.